A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects With Essential Hypertension

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects With Essential Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Azilsartan medoxomil (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 29 Sep 2016 Primary endpoint has been met. (Change from Baseline to Week 6 in Trough Clinic Sitting Systolic Blood Pressure (SBP))
    • 29 Sep 2016 Results presented at the 26th Scientific Meeting of the International Society of Hypertension
    • 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top